Skip to main content
Fig. 4 | BMC Cancer

Fig. 4

From: Activated thrombin-activatable fibrinolysis inhibitor (TAFIa) attenuates breast cancer cell metastatic behaviors through inhibition of plasminogen activation and extracellular proteolysis

Fig. 4

The effects of PTCI, TM and TAFIa on breast cancer cell migration. a SUM149 and MDA-MB-231 cells were subjected to migration assays in the presence of 10 μg/mL PTCI or 10 nM TM or in the absence of these additions (Control). The number of migrated cells were imaged and counted in five fields of view. Images shown were taken at 4× magnification. Scale bars: 200 μm. b Quantification of migrated cells, relative to control (absence of treatment). The data represent the average cell number per field of view ± SEM from at least 4 independent experiments. *: p <0.05 and **: p <0.01 relative to control. c Cells were treated with varying concentrations of either TAFIa-WT or TAFIa-CIIYQ (1–50 nM) for 24 h. Cells were also treated with 50 nM mock-activated TAFI-WT or TAFI-CIIYQ (Non-Activated). Migration was imaged as in (a). d Quantification of migrated cells, relative to control in the absence of TAFIa. The data represent the average cell number per field of view ± SEM from at least three independent experiments. *: p <0.05 relative to control; #: p <0.05 relative to TAFIa-WT

Back to article page